Siponimod for patients with relapsing-remitting MS
Posted: Wed Jun 12, 2013 6:52 am
Siponimod for patients with relapsing-remitting MS (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Background
Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days. We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with relapsing-remitting multiple sclerosis....... Read More - http://www.ms-uk.org/index.cfm/emergingtherapies
Background
Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days. We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with relapsing-remitting multiple sclerosis....... Read More - http://www.ms-uk.org/index.cfm/emergingtherapies